PRESS-RELEASE filed May 12, 2026 at 07:00 ET
Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21.4M YoY due to lower collaboration cost recognition. The net loss widened to $66.5M from a prior-year net profit of $45.9M, driven by higher R&D spending on the SUPRAME Phase 3 trial and early commercial preparations. The stock's move will hinge on the upcoming SUPRAME interim/final analysis triggers in 2026 and multiple ASCO data readouts, not the mixed quarterly financials.